光大证券晨会速递-20250924

Group 1: Industry Research - The core viewpoint of the cobalt industry report indicates that the extension of the cobalt export ban in the Democratic Republic of Congo (DRC) until October 15, 2025, followed by a quota system, is expected to lead to a significant reduction in cobalt supply, which will positively impact cobalt prices. The DRC is projected to account for 76.3% of global cobalt production in 2024 [1] - Investment recommendations include Huayou Cobalt and Luoyang Molybdenum, with a focus on Likin Resources as a potential opportunity [1] Group 2: Company Research - The report on China Railway Construction (300374.SZ) highlights that the company achieved stable revenue growth in the first half of 2025, with a further reduction in net profit losses and improvements in cash flow and collection ratios compared to the previous year. The forecast for net profit attributable to shareholders for 2025-2027 is maintained at 0.02 billion, 0.44 billion, and 0.68 billion respectively, with a recommendation to "increase holdings" [2] - The report on Amengke Pharmaceutical (688373.SH) discusses a planned capital increase where Nanjing Haiqing Pharmaceutical will acquire 20% of the company for up to 1.033 billion yuan at a price of 6.3 yuan per share. This move is expected to enhance the company's sales and production capabilities, with projected net profits for 2025-2027 at -2.41 billion, -1.90 billion, and -0.99 billion respectively, maintaining a "buy" rating [3]